The double burden of disease in developing countries: the Mexican experience.
OBJECTIVE
To present the challenges arising from the double burden of disease in developing countries, focusing on the case of Mexico, and to propose a strategy for addressing these challenges.


METHODS
Mortality and morbidity data are presented for selected countries and groups of diseases. Specific examples of the pressures faced by the public health services in Mexico to provide and finance treatment for communicable and non-communicable diseases are used to illustrate the extent of the challenges in the context of a country with limited resources.


RESULTS
Public health systems in developing countries face strong pressure to provide and finance treatment for both communicable and non-communicable diseases, inevitably producing competition among diseases and conditions and requiring trade-offs between equity and efficiency goals.


CONCLUSIONS
In developing countries, addressing the challenges presented by the double burden of disease requires a multidisciplinary approach to develop and strengthen the policymaking process. This involves the use of analytical tools applied to each stage of the planning cycle, in particular the use of an explicit priority setting process together with monitoring and assessment to strengthen decision making under limited resources.
Economic Analysis Unit, Ministry of Health, Mexico.
Cristina
C
Gutiérrez-Delgado
Veronica
V
Guajardo-Barrón
D044966:Anti-Retroviral Agents / Q000191:economics; D002908:Chronic Disease / Q000191:economics* / Q000453:epidemiology; D003141:Communicable Diseases / Q000191:economics* / Q000453:epidemiology; D003906:Developing Countries; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000191:economics; D017048:Health Care Costs; D006291:Health Policy; D006801:Humans; D008800:Mexico / Q000453:epidemiology; D009017:Morbidity; D009026:Mortality; D015980:Public Health Practice; D017582:Renal Replacement Therapy / Q000191:economics; D002583:Uterine Cervical Neoplasms / Q000191:economics / Q000517:prevention & control
D044966:Anti-Retroviral Agents